One of the best predictors for a good outcome after total knee arthroplasty (TKA) is early knee mobilization, which can be difficult to acquire if the patient is in pain (Mauerhan et al. [@C28], Bong and Di Cesare [@C5], Scuderi [@C33], Gandhi et al. [@C12]). Postoperative pain after TKA is moderate to severe (Andersen et al. [@C2], Wylde et al. [@C39]), which delays ambulation (Wu and Richman [@C38]) and prolongs hospital stay (Essving et al. [@C9], Husted et al. [@C18]). A multimodal analgesia regimen seems to be the most effective way of treating postoperative pain after TKA (Vendittoli et al. [@C36], Amantullah [@C1]) which may include pain medications, local infiltration anesthesia (LIA) and peripheral nerve blocks (PNB). LIA gives good pain control without affecting muscle strength (Kerr and Kohan [@C24], Essving et al. [@C10]) and has been shown to give similar pain scores and shorter lengths of stay when compared with PNB (Spangehl et al. [@C34]).

After TKA the quadriceps muscle plays a key role for ambulation. Several factors affect its strength, such as PNBs, pain and surgical trauma (Greene and Schurman [@C13]). PNBs have proved their worth in postoperative pain management after TKA (Amantullah [@C1]) but one of their biggest disadvantages is reduced muscle strength. Femoral nerve block (FNB) gives good pain relief after TKA (Paul et al. [@C31]) but affects the quadriceps muscle strength (Jaeger et al. [@C21]) and may increase the risk of falls (Ilfeld et al. [@C19], Johnson et al. [@C23]). Compared with FNB, adductor canal block (ACB) seems to preserve the quadriceps muscle strength better yet giving similar analgesic effect (Jaeger et al. [@C21], Kim et al. [@C25], Mudumbai et al. [@C29], Wiesmann et al. [@C37]). For those reasons, ACB has been tried as an alternative to FNB.

The saphenous nerve courses the adductor canal in the medial part of the thigh. A recent study showed that the nerve to vastus medialis (NVM) courses the canal more often than previously thought and most likely plays a major role in the sensory innervation of the knee (Burckett-St Laurant et al. [@C6]).

Placebo-controlled studies on ACB after TKA have shown promising results regarding pain relief, especially on the day of surgery, and have also been shown to improve patient ambulation (Jaeger et al. [@C20], Jenstrup et al. [@C22]). ACB is a relatively safe procedure (Henningsen et al. [@C16]) and can lead to lower morphine consumption compared with placebo (Jenstrup et al. [@C22], Hanson et al. [@C15]).

As described above, LIA and ACB seem to work well separately after TKA in randomized controlled trials (RCT) and many of the published studies on ACB have focused on the effects of the block on the day of surgery (Jaeger et al. [@C20], Jenstrup et al. [@C22], Jaeger et al. [@C21]). We found only 1 study where ACB was added to a single-dose LIA, where no other blocks were used. The primary end point of that study was worst pain during movement on POD0 (Andersen et al. [@C3]). We wanted to focus on the analgesic effects of the block on pain and ambulation abilities on POD1 and POD2 by using validated physiotherapy tests. Therefore, this prospective, randomized, double-blind, placebo-controlled trial compared the effects of a continuous infusion ACB added to an intraoperative single-dose LIA after TKA. We hypothesized that in addition to LIA, a continuous infusion ACB would lower pain scores while ambulating on POD1 (primary endpoint), enhance ambulation ability, improve pain relief at rest, decrease opioid consumption and shorten the hospital stay (secondary endpoints).

Patients and methods {#s0002}
====================

This prospective, randomized, double-blind, placebo-controlled trial was conducted at the Akureyri Hospital from October 2015 through May 2016. Eligible participants, screened for inclusion, were patients scheduled for primary unilateral cemented TKA under spinal anesthesia, aged 50--90 years, with ASA physical status I--III. Exclusion criteria were daily intake of opioids (≥ 20 mg/day of oral morphine equivalent for \>12 weeks), inability to cooperate, peripheral neuropathy, allergy to any of the study medications and renal insufficiency (creatinine levels \>100 μmol/L and \>110 μmol/L for women and men respectively).

Randomization and blinding {#s0003}
--------------------------

Randomization was done by a secretary using a computer-generated randomization list (Research randomizer, [www.randomizer.org](http://www.randomizer.org)) in a 1:1 ratio with 20 numbers in each block. Every participant received a consecutive study number from 1 to 69 and received the treatment assigned according to the randomization list. The list was stored and only 2 nurses, who prepared the study medications, had access to it. They had no interactions with the patients. All other clinical personnel, participants and outcome assessors were blinded to the intervention. The randomization key was first broken when all enrolled patients had completed the study. After discharge, the participant's personal information was eliminated from the study number and was therefore not traceable back to the patient.

Interventions {#s0004}
-------------

Premedication consisted of 1.5 g acetaminophen and 10--20 mg oxycodone, according to the participant's weight. Prophylactic medication (ondansetron 4 mg i.v., dexamethasone 8 mg i.v. and haloperidol 1 mg i.v.) for postoperative nausea was given if the patient had a prior history of postoperative nausea.

Spinal anesthesia was induced with bupivacaine 5 mg/mL according to patients' BMI (BMI \<20 = 2.8 mL, BMI 20--35 = 3.2 mL, BMI \>35 = 3.4 mL). This was administered at the L2--L3 or L3--L4 vertebral interspaces along with 15 μg of fentanyl. Propofol sedation during surgery was given if required.

Surgical technique and prosthesis selection were left to each of the 4 individual surgeons and all procedures were done in a bloodless field using a femoral tourniquet. 102 mL of LIA was distributed to the posterior capsule, the medial and lateral retinaculum and the subcutaneous tissue according to the method of Guild et al. ([@C14]). The LIA consisted of 200 mg ropivacaine, 30 mg ketorolac and 0.5 mg adrenaline.

According to the randomization list a total amount of 500 mL of study medication, either 0.2% ropivacaine or normal saline, was prepared by either of the 2 un-blinded nurses immediately postoperatively. 480 mL were divided equally into 2 boxes and 20 mL put in a syringe.

The ACB, with placement of a perineural catheter, was performed in the post-anesthesia care unit before the spinal anesthesia had worn off. All the catheters were placed in a sterile fashion by 1 of the 5 attending anesthesiologists. Under ultrasound guidance at mid-thigh level the adductor canal was identified and an 18-gauge Tuohy needle was inserted into the canal. A 20 mL bolus of the study drug was then given. The decision on the bolus volume was based on the amount needed to fill the canal without risking a retrograde flow to the femoral triangle (Lund et al. [@C27], Andersen et al. [@C4]). A 22-gauge epidural catheter was then placed through the Tuohy needle and threaded 5 cm into the canal. The position was confirmed with an injection of 2--3 mL of normal saline. 4 hours after the initial bolus, a continuous infusion of the study drug was initiated at 6 mL/h for 48 hours, calculated to be within the toxic effects of the ropivacaine when taking into account the ropivacaine in LIA and in the initial bolus (Kuthiala and Chaudhary [@C26]). The catheter was removed on postoperative day 2 (POD2) after the morning physiotherapy (PT) session.

Unless contraindicated, all patients received a standardized analgesic regimen postoperatively consisting of oral acetaminophen 1 g x 4, oral oxycodone 10--20 mg (according to BMI) x 2 and intravenous parecoxib 40 mg x 1. If needed, patients were given additional oral or intravenous pain medication (fast-release oxycodone, ketobemidon, morphine or codeine).

outcome measures {#s0005}
----------------

Preoperatively we collected demographic data and registered if patients had a prior TKA of the other knee. We assessed maximum knee flexion, straight leg raise (SLR) and estimated the quadriceps muscle strength of the affected knee ([Table 1](#TB1){ref-type="table"}).

###### 

Demographics and preoperative data

                                           Treatment (n = 35)   Control (n = 34)
  ---------------------------------------- -------------------- ------------------
  Age **^**a**^**                          71 (60--87)          68 (55--85)
  Sex (male/female)                        17/18                16/18
  BMI                                      31 (22--56)          31 (23--45)
  ASA score I/II/III                       2/28/5               5/28/1
  Preoperative knee flexion                110 (89--123)        110 (89--125)
  Preoperative quadriceps strength         5 (1--5)             5 (3--5)
  Preoperative nausea I/II/III/IV          1/0/0/0              0/0/0/0
  Preoperative straight leg raise yes/no   33/1                 34/0

Data are counts, median (range) or **^a^** mean (range)

Primary end point {#s0006}
-----------------

The primary end point was peak pain level in the operated knee during morning PT session on POD1. Patients were instructed to record their pain, at the time of the assessment, on the numerical rating scale (NRS-11) (Hjermstad et al. [@C17]), where 0 indicates no pain and 10 indicates worst possible pain.

Secondary end points {#s0007}
--------------------

In the same way as the primary end point the peak pain level in the operated knee was recorded on POD2. Pain at rest was measured on the NRS-11 scale immediately before the morning PT session on POD1 and POD2. Morphine consumption and additional pain medication was recorded and calculated into Oral Morphine Equivalents (OMEQ) (Svendsen et al. [@C35]). Time from the end of surgery until first additional pain medication was given was recorded. We documented the day participants were able to climb stairs and when they fulfilled the following criteria for discharge: (a) able to walk with crutches, (b) sufficient oral analgesia, (c) knee flexion ≥70°, (d) ability to climb stairs and (e) no acute medical problems present (if patients failed to meet the criteria before discharge their data were treated as missing). The actual length of stay was also recorded.

All the ambulation ability assessments, apart from the timed up and go (TUG) test (Yeung et al. [@C40]), were done in the morning of both POD1 and POD2 by 1 of the 4 physiotherapists in the department. These were the degree of active knee flexion, quadriceps muscle strength, SLR and the measurements on the 10-point mobility scale (Jaeger et al. [@C21]). The TUG test was performed in the morning of POD2. It measures the time it takes the patient to stand up from a chair, walk 3 meters, and return to a sitting position in the chair. The 10-point mobility scale evaluates whether the subject can achieve 5 predefined goals of ambulation with or without help of the physiotherapist. Quadriceps muscle strength was assessed by the ability of the patient to hold the affected limb up with the knee extended against resistance of the examiner (using manual muscle testing (MMT) with 0 = no contraction, 1 = flicker of contraction, 2 = active movement with gravity eliminated, 3 = active movement against gravity but not resistance, 4 = active movement against gravity and some resistance and 5 = normal strength). Finally, the SLR was successful if the participant could hold the lower limb 10 cm from the bed with fully extended knee for 10 seconds.

If there was a sign of irritation, allergy or infection at the catheter site the intervention was stopped and the patient was excluded from further participation.

Statistics {#s0008}
----------

We used G\*Power 3 for our power analysis (Faul et al. [@C11]). 27 participants were required in each group to demonstrate a significant difference of 1 (1.1 SD) on the NRS-11 scale for the primary outcome with a probability of a 2-tailed type I error of 0.05 and a power of 90%. 15 additional subjects were recruited into the study to prevent loss of power due to early withdrawal and to compensate for uncertainty regarding our estimated SD.

Statistical analyses were performed using IBM SPSS® version 20 (IBM Corp, Armonk, NY, USA). We used the Shapiro--Wilk test to assess normality. Normally distributed variables were compared using Student's t-test. Pearson's chi-square test was used for categorical variables but if the minimum expected data count was \<5 we used Fisher's exact test. For the not normally distributed data, we used the Mann--Whitney U-test.

Though the NRS pain-score is commonly thought of as an ordinal scale we decided to follow Dexter and Chestnut ([@C8]) and treat the peak NRS pain score at the PT sessions as normally distributed data. We also ran a Shapiro--Wilk test on the variables, which further confirmed that they were normally distributed. Pain at rest did not follow these rules of normality and is therefore treated as other non-normally distributed data.

All p-values were calculated 2- tailed, and a p-value of less than 0.05 was considered statistically significant.

Ethics, registration, funding and conflicts of interest {#s0009}
-------------------------------------------------------

Approval was obtained from the local Regional Ethics Committee of Akureyri Hospital and the Icelandic Data Protection Authority (25.08 2015 nr: 3/2015). Written informed consent was obtained from all participants and the study was conducted in accordance with the Declaration of Helsinki. The study was registered at ISRCTN registry (ISRCTN68176033). The study received funding from Akureyri Hospital Scientific fund (Vísindasjóður Sjúkrahússins á Akureyri) and Akureyri Medical Staff Scientific Fund (Vísindasjóður Læknaráðs, Sjúkrahússins á Akureyri). No competing interest declared.

Results {#s0010}
=======

88 patients were approached for participation from October 2015 to May 2016. 69 were included and randomly assigned to treatment (n = 35) or control group (n = 34) ([Figure 1](#F0001){ref-type="fig"}). Preoperative measurements and demographic data were similar between the groups ([Table 1](#TB1){ref-type="table"}).

![Flow chart of the study.](iort-88-537.F01){#F0001}

Peak pain score during PT session on POD1 (primary end point) showed no significant difference between the 2 groups (p = 0.3). For the same measurement on POD2 we found no significant difference (p = 0.9).

The ambulation-ability tests were similar on POD1 and POD2 ([Table 2](#TB2){ref-type="table"}). On POD2 we found significant difference (p = 0.04) on the 10-point mobility scale in favor of the control group. There was 1 participant in the treatment group who showed extremely poor results and when excluded the difference was no longer significant (p = 0.07). The number of individuals reaching discharge criteria on POD2 and the actual length of stay was similar between the groups. The treatment group showed significantly lower pain scores at rest in the morning of POD1 (p = 0.04) but not on POD2 (p = 0.4). Grouping the patients' pain scores into moderate pain (NRS 3--6) versus strong pain (NRS \>7) did not alter our findings. Total morphine consumption and time to first additional pain medication given were similar between the groups ([Table 3](#TB3){ref-type="table"}).

###### 

Ambulation abilities

                                                                Treatment      Control        
  ------------------------------------------------------------- -------------- -------------- ---------
  POD1:                                                         n = 35         Pn =34         
  POD2:                                                         n = 30         Pn =31         p-value
  Quadriceps strength POD1                                      4 (1--5)       4 (2--5)       0.9
  Quadriceps strength POD2                                      5 (1--5)       5 (1--5)       0.9
  Active knee flexion POD1                                      83 (50--100)   80 (45--100)   0.8
  Active knee flexion POD2                                      90 (30--110)   90 (65--105)   0.4
  Straight leg raise POD1[^a^](#TF3){ref-type="table-fn"}       29/3           33/1           0.4
  Straight leg raise POD2[^a^](#TF3){ref-type="table-fn"}       28/1           30/1           1.0
  Climbing stairs POD1[^a^](#TF3){ref-type="table-fn"}          5/27           1/33           0.1
  Climbing stairs POD2[^a^](#TF3){ref-type="table-fn"}          26/4           24/7           0.5
  TUG test (seconds) POD2                                       24 (0--59)     25 (0--58)     0.4
  Ready for discharge on POD2[^a^](#TF3){ref-type="table-fn"}   26/2           25/5           0.4
  10-point mobility scale POD1                                  10 (3--10)     10 (5--10)     0.6
  10-point mobility scale POD2                                  10 (1--10)     10 (10--10)    0.04

Data are counts or median (range)

yes/no

###### 

Pain scores and morphine consumption

                                                               Treatment       Control
  -------------------------------------------- --------------- --------------- ---------
  POD1:                                        n = 35          Pn =34          
  POD2:                                        n = 30          Pn =31          p-value
  NRS during PT session POD1 **^**a**^**       6 (1--9)        6 (1--10)       0.3
  NRS during PT session POD2 **^**a**^**       5 (0--10)       5 (2--10)       0.9
  NRS at rest POD1                             1 (0--6)        3 (0--5)        0.04
  NRS at rest POD2                             1 (0--6)        2 (0--5)        0.4
  NRS \>3/\< 3 at rest POD1                    4/28            8/26            0.3
  NRS \>3/\< 3 at rest POD2                    2/28            4/27            0.4
  Time to additional pain medication (hours)   7.5 (0.5--47)   8.0 (0.5--47)   0.9
  OMEQ total POD0                              38 (15--100)    53 (15--96)     0.4
  OMEQ total POD1                              45 (8--130)     53 (30--145)    0.3
  OMEQ total POD2                              41 (8--85)      45 (15--175)    0.3

Data are counts, median (range) or **^a^** mean (range)

NRS = Numeric rating scale (for assessment of pain intensity)

PT = Physiotherapy

OMEQ = Oral morphine equivalents

Leakage from the injection site of the catheter developed in 8 participants, 4 in the control group and 4 in the treatment group. No evidence of a visible infection at any catheter site was found during routine follow-up and no falls were recorded in either group.

21 patients who had an earlier TKA done on the other knee were equally distributed between the 2 groups. They were significantly older (p = 0.03) but were similar in other measurements.

Discussion {#s0011}
==========

The aim of this trial was to evaluate the adjunctive effect of a continuous ACB added to a single-dose LIA on pain and ambulation after TKA. Our primary endpoint, pain while ambulating on POD1, was not statistically significantly different between the two groups.

Our results contribute to the decision on whether a continuous ACB should be added to a single-dose LIA after TKA to help with ambulation after the day of surgery. The ACB did not aid in performing the TUG test on POD2 nor did the treatment group show any superiority in other ambulation testing on either POD1 or POD2. These results are comparable to a randomized placebo-controlled trial conducted by Andersen et al. ([@C3]) who observed no difference in pain during movement on POD1 and POD2 in subjects after TKA with continuous ACB added to LIA. In that study no validated physiotherapy testing was used to compare the groups and boluses were used for the ACB instead of infusion.

The effect of ACB on pain and mobilization after TKA has previously been shown to have good effects on POD0 (Jaeger et al. [@C20], Jenstrup et al. [@C22]). The reason why we did not see the same effect of the continuous infusion on POD1 and POD2 is unclear. Andersen et al. ([@C3]) did an ultrasound of the spread of the injectate during the last bolus of ACB on POD2 which showed that 5 out of 8 catheters were displaced out of the canal. Another reason could be that a continuous flow of 6 mL/h is not enough to affect the nerves in the canal.

There are case reports (Chen et al. [@C7], Neal et al. [@C30]) showing that ACB can affect the muscle strength of the quadriceps muscle, which can lead to lower ambulation abilities, but this seems to be rare. Other studies have shown generally better quadriceps functions after TKA in patients who are given ACB compared with placebo (Jaeger et al. [@C21], Hanson et al. [@C15]). We therefore doubt that weakness of the quadriceps muscle is the reason why we found no difference between the 2 groups in ambulation abilities.

Our treatment group showed lower pain scores at rest in the morning of POD1. This finding is not supported in other studies on continuous ACB to placebo (Jenstrup et al. [@C22]) or to LIA alone (Andersen et al. [@C3]). Due to multiple tests there is a risk of a type I error. Hence, we do not want to emphasize the single significant result found and must consider it a coincidence. However, as previously mentioned ACB has showed promising effects on POD0 after TKA. The single-shot bolus given after the surgery could be having some residual effects in the morning of POD1 when it comes to pain at rest. If this finding is not a coincidence we doubt its clinical relevance based on the fact that we did not see it resulting in better ambulation abilities or lower morphine consumption on POD1 or POD2.

There are several limitations to this study. To be within the time frame of the study and to fulfill the requirements of the power analysis we had to accept a few deficiencies. 4 orthopedic surgeons performed the operations, though all are experienced with LIA. 5 anesthesiologists performed the ACB, all experienced with ultrasound-guided PNBs and 4 physiotherapists did the ambulation-ability tests. The results therefore reflect the real-life setting, which may weaken the internal validity but on the other hand strengthen the external validity of the trial. We did not use patient-controlled anesthesia, which might have given us more accurate results on the need for additional pain medication. We did not check the success rate of the block, mainly to keep all the staff and the study participants blinded to the treatment group. In that way, we cannot know for sure that the blocks given were all functioning correctly but research has shown about 95% success rates of the adductor canal block (Saranteas et al. [@C32], Jenstrup et al. [@C22]). The disadvantage of giving a continuous-flow ACB rather than boluses is that the patients need to carry a pump, which might affect their ambulation abilities, but should not lead to any bias. The strengths of our trial include its randomized design, the successful blinding process and its consistent approach in standardizing the pre- and postoperative medication. It also was adequately powered for the primary end point.

In conclusion, our results indicate no benefit of continuous-infusion ACB added to a single-dose LIA compared with LIA alone on pain while ambulating on POD1 and POD2. Furthermore, the block showed no superiority in ambulation abilities on these 2 postoperative days. Further research is needed to address the adjunctive effects the block provides to LIA on the day of surgery with primary focus on the ambulation.
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